Last reviewed · How we verify

Sabin IPV + Sabin IPV + Sabin IPV

Zhejiang Provincial Center for Disease Control and Prevention · FDA-approved active Biologic

Sabin IPV is an inactivated polio vaccine that stimulates the immune system to produce antibodies against all three poliovirus serotypes (1, 2, and 3).

Sabin IPV is an inactivated polio vaccine that stimulates the immune system to produce antibodies against all three poliovirus serotypes (1, 2, and 3). Used for Prevention of poliomyelitis caused by poliovirus types 1, 2, and 3.

At a glance

Generic nameSabin IPV + Sabin IPV + Sabin IPV
SponsorZhejiang Provincial Center for Disease Control and Prevention
Drug classinactivated viral vaccine
Targetpoliovirus serotypes 1, 2, and 3
ModalityBiologic
Therapeutic areaImmunology / Infectious Disease
PhaseFDA-approved

Mechanism of action

Sabin IPV contains inactivated (killed) poliovirus particles that trigger humoral and cellular immune responses without causing disease. The vaccine elicits production of neutralizing antibodies against poliovirus types 1, 2, and 3, providing protection against poliomyelitis. The triple formulation ensures comprehensive coverage against all circulating wild-type and vaccine-derived poliovirus strains.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: